Kelun-Biotech’s ITGB6 ADC SKB105 Wins NMPA IND Approval
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Investigational New Drug (IND) application...
Huadong Medicine Licenses MC2’s PAD‑Based Biomee Skincare for Greater China
Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly‑owned...
CMS Unveils BALANCE Model to Expand GLP-1 Access for Medicare/Medicaid
The U.S. Centers for Medicare & Medicaid Services (CMS) unveiled the BALANCE Model (Better Approaches...
GenEditBio’s GEB-101 Wins FDA IND Approval as World’s First Corneal Gene Therapy
GenEditBio announced that GEB-101, its self‑developed in vivo genome editing investigational drug, has received Investigational...
Merck’s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world’s...
Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
Aspen Holdings announced a binding agreement for its wholly‑owned subsidiary Aspen Global Incorporated (AGI) to...
China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
The National Medical Products Administration (NMPA) announced that China approved 76 innovative drugs for marketing...
China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
Novo Nordisk (NYSE: NVO) announced that China’s Supreme People’s Court upheld the Beijing IP Court ruling,...
Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical...
Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio
Genmab A/S (NASDAQ: GMAB) announced it will discontinue clinical development of acasunlimab, a PD‑L1 x...
NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support
The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged...
Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy
Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making...
China State Council Approves Revised Drug Administration Regulations, Accelerating Innovation Review
The State Council of China approved the Revised Draft of the Implementation Regulations of the...
Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced a licensing agreement with Adlai Nortye Ltd...
HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China’s National Medical Products Administration (NMPA)...
NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
NeuroGen Pharma, a China‑based neurology‑focused biopharmaceutical company co‑founded by CBC Group and Mubadala in 2024,...
Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement...
Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Sirius Therapeutics announced that the first patient has been dosed in a Phase II clinical trial...
Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock...
Broncus Medical Acquires Valgen Stake from Venus for $15 Million
Broncus Medical (HKG: 2216) announced that its wholly‑owned subsidiary, Broncus China Holding Corporation, has agreed...